Currently, there are 208.54M common shares owned by the public and among those 197.48M shares have been available to trade.
The company’s stock has a 5-day price change of 7.93% and 6.43% over the past three months. BCRX shares are trading 12.23% year to date (YTD), with the 12-month market performance up to 102.88% higher. It has a 12-month low price of $4.11 and touched a high of $9.50 over the same period. BCRX has an average intraday trading volume of 3.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.18%, 7.84%, and 8.79% respectively.
Institutional ownership of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) shares accounts for 78.39% of the company’s 208.54M shares outstanding.
It has a market capitalization of $1.77B and a beta (3y monthly) value of 1.08. The earnings-per-share (ttm) stands at -$0.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.36% over the week and 5.93% over the month.
Earnings per share for the fiscal year are expected to increase by 78.29%, and 316.09% over the next financial year.
Looking at the support for the BCRX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on April 29, 2025, with the firm’s price target at $20. Wedbush coverage for the Biocryst Pharmaceuticals Inc (BCRX) stock in a research note released on February 25, 2025 offered a Outperform rating with a price target of $15. JP Morgan was of a view on November 20, 2023 that the stock is Overweight, while RBC Capital Mkts gave the stock Outperform rating on September 18, 2023, issuing a price target of $9- $10. Jefferies on their part issued Buy rating on August 04, 2023.
